Efficacy of nuclear medicine imaging to detect fibroblast activation protein in pancreatic and biliary tract cancer.

Pilot study for the association between fibroblast and clinicopathologic features in pancreatic cancer and cholangiocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009207

Enrollment

Registered

2024-02-27

Start date

2021-10-05

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : FAPI PET/CT obtained torso images at 60 and 120 minutes after maintaining a stable state after intravenous injection of 185 MBq (5 mCi) of FAPI. Torso imaging takes about 10 minutes in total

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Adults over 20 years old - Patients suspected of having pancreatic cancer or biliary tract cancer on imaging tests including CT and PET/CT and confirmed to have cancer on biopsy - Patients in whom cancer was not confirmed on biopsy due to difficulty in histological examination before surgery, but surgical treatment was planned due to strong suspicion of cancer based on clinical picture and imaging examination - Patients who can provide written consent and comply with the research requirements before starting to participate in the study. - Patients who gave written consent to establish a Bio Repository for liver, biliary tract, and pancreatic tumor research (H-0901-010-267)

Exclusion criteria

Exclusion criteria: - Patients who are pregnant or lactating - Patients with a history of clinically significant uncontrolled seizures, central nervous system disease, or mental illness that, in the opinion of the investigator, may interfere with or interfere with the subject's ability to understand the consent form. - Subjects who develop uncontrolled severe infection or other uncontrolled serious comorbidities - Patients who have undergone other major surgery within 4 weeks prior to the study or who have not fully recovered from the effects of major surgery.

Design outcomes

Primary

Measure	Time frame
Differences in measured variables related to expression of cancer associated fibroblasts according to clinical characteristics and tumor stage (T-stage, N-stage)	—

Secondary

Measure	Time frame
Verification of correlation between variables measured in CT, FDG PET, FAPI PET and quantitative indices of RNA and Protein obtained from postoperative tissues	—

Countries

Korea, Republic of

Contacts

Public ContactWon-Gun Yun

Seoul National University Hospital

wkeonyun@gmail.com+82-2-2072-2194

Outcome results